American Tower Guides FY24 Property Revenue In Line With Estimates - Update

RTTNews | 477日前
American Tower Guides FY24 Property Revenue In Line With Estimates - Update

(RTTNews) - While reporting its financial results for the fourth quarter on Tuesday, American Tower (AMT) initiated its property revenue for the full-year 2024.

For fiscal 2024, the company now projects total property revenue in a range of $11.05 billion to $11.23 billion, net income in a range of $3.305 billion to $3.415 billion, adjusted EBITDA in a range of $7.080 billion to $7.190 billion, and consolidated AFFO in a range of $10.21 to $10.45 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.87 per share on revenues of $11.22 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
American Tower Q2 Profit Nearly Doubles; Boosts FY24 Outlook

American Tower Q2 Profit Nearly Doubles; Boosts FY24 Outlook

American Tower (AMT) reported Tuesday that net income attributable to the company for the second quarter nearly doubled to $900.3 million or $1.92 per share from $475.7 million or $1.02 per share in the prior-year quarter.
RTTNews | 323日前
CPI Softening Boosts FTSE 100

CPI Softening Boosts FTSE 100

Better-than-expected CPI readings from the U.K. bolstered sentiment, helping FTSE 100 outperform its peers.
RTTNews | 3分前
CAC 40 Retreats After Short-lived Rebound

CAC 40 Retreats After Short-lived Rebound

Despite attempting a rebound, the CAC 40 index that tracks the 40 largest French stocks based on the Euronext Paris has shed around half a percent in Wednesday's trading.
RTTNews | 1時8分前
FDA Launches Commissioner's National Priority Voucher Program

FDA Launches Commissioner's National Priority Voucher Program

The U.S. Food and Drug Administration announced launch of a new program to issue Commissioner's National Priority Vouchers or CNPVs, which shortens review time significantly, with a view to support national health priorities. The new CNPV program, which will begin in 2025, aims to accelerate the drug review process for companies while maintaining the FDA's rigorous standards for safety, efficacy..
RTTNews | 1時20分前